We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 186,038 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
TIDMSBTX
SkinBioTherapeutics PLC
19 June 2017
SkinBioTherapeutics plc
SkinBioTherapeutics to Present at Investor Evening
Manchester, UK - 19 June 2017 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, is pleased to announce that Dr Catherine O'Neill (CEO) will be presenting at an investor evening held in London, EC4 hosted by Turner Pope Investments (TPI) Ltd.
The event will be held on Thursday 29(th) June and will commence at 5pm.
To register your interest, please email info@turnerpope.com or call 0203 621 4121.
Ends
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468 Dr. Catherine O'Neill, 2760 CEO Douglas Quinn, CFO Turner Pope Investments Tel: +44 (0) 20 3621 Ben Turner / James Pope 4120 Instinctif Partners Tel: +44 (0) 20 7457 Melanie Toyne-Sewell / 2020 Alex Shaw / Deborah Bell SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXKNFSEXEEF
(END) Dow Jones Newswires
June 19, 2017 04:00 ET (08:00 GMT)
1 Year Skinbiotherapeutics Chart |
1 Month Skinbiotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
